Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (3292 companies, A–Z).
Green Plains entered into a Tax Credit Purchase Agreement on October 29, 2026, to transfer Section 45Z clean fuel production tax credits from its 2026 ethanol production to two unaffiliated buyers. The deal covers a minimum of $250 million and up to $325 million in credits, and the company expects $140 million of cash in the fourth quarter for credits generated through June 30, 2026.
Minimum of $250 million and maximum of $325 million in 2026 Section 45Z credits, subject to generation and conditions
Company expects $140 million cash in Q4 2026 for credits generated through June 30, 2026
Credits from Q3 and Q4 2026 expected to be monetized in the first half of 2027
If a tax law change limits transferred credits, Green Plains must return the related purchase price with interest
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX on October 26, 2026, under which ZEO would receive an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, with Pluri receiving equity in ZEO at closing. On October 27, 2026, Pluri agreed to sell 909,092 common shares and warrants to two investors for $1.0 million in total, with closing expected on or before October 30, 2026. The stock sale adds shares outstanding, and the ZEO transaction depends on closing conditions, including agreement on an operating plan.
October 26, 2026: ZEO partnership grants ZEO an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, excluding certain aesthetics, skin care, cosmetic, or veterinary uses, which ZEO may only commerci
At closing, Pluri is to receive 41% of ZEO's issued and outstanding shares plus 50 Series D Preferred shares carrying 51% of ZEO's votes
October 27, 2026: two Securities Purchase Agreements for 909,092 common shares at $1.10 per share, with warrants for an equal number of shares at $1.30 per share; closing expected on or before October 30, 2026
Markel's insurance subsidiaries entered an Adverse Development Cover Agreement with Cavello Bay Reinsurance, a wholly owned subsidiary of Enstar Group Limited, covering $4.8 billion of net reserves on a run-off global reinsurance portfolio and certain exited lines. Markel will pay a $2.4 billion reinsurance premium, settled through a transfer of assets at closing, and the deal is expected to close by the end of the fourth quarter of 2026 subject to regulatory approval. Markel's press release says the net impact on fourth quarter underwriting results is expected to be immaterial.
Subject reserves of $4.8 billion; Markel retains the first $2.6 billion of covered losses, and the reinsurer covers the next $2.3 billion.
Adverse development coverage of $1.2 billion above the $4.8 billion of reserves.
Reinsurance premium of $2.4 billion, with $500 million of transferred assets sent to the reinsurer outright and the balance placed in a trust account.
Closing expected by the end of the fourth quarter of 2026, subject to regulatory approval; the agreement covers losses paid on or after April 1, 2026.
3M entered into an expanded strategic commercial relationship with a subsidiary of Amazon.com, Inc. and issued that subsidiary a seven-year warrant to buy up to 3,162,015 shares of 3M common stock at $164.89 per share. The filing says 85% of the warrant shares vest based on Amazon payments for optical connectivity and other Data Center products, with full vesting once cumulative payments reach $6 billion. For shareholders, the warrant adds potential dilution, though its vesting ties it to future purchases.
Warrant covers up to 3,162,015 shares of 3M common stock over seven years
Exercise price is $164.89 per common share
85% of warrant shares vest with Amazon payments for optical connectivity and other Data Center products; full vesting at $6 billion in cumulative payments
Remaining warrant shares vest subject to event-based milestones not specified in the filing
NioCorp's majority-owned subsidiary Elk Creek Resources signed an Offtake Agreement with Traxys North America on October 13, 2026, replacing prior ferroniobium and scandium offtake agreements with Traxys. The deal gives Traxys take-or-pay purchase rights on 50% of annual ferroniobium output and exclusive marketing rights for 100% of other Elk Creek products, which matters to shareholders because it sets the sales framework for the project's planned output.
Agreement dated October 13, 2026, between Elk Creek Resources and Traxys North America LLC
Traxys to buy 50% of annual ferroniobium production on a take-or-pay basis, or 3,700 metric tonnes per year at Traxys' election
Term of 15 years from the Commercial Production Date, followed by two automatic one-year renewals
Either party may terminate if the Export-Import Bank of the United States has not given final approval of senior debt financing by December 31, 2027
On October 5, 2026, BioNexus Gene Lab Corp. agreed to an exclusive Malaysian healthcare licence to Ruanyun Edai Technology's CogniAI document-intelligence platform, with closing still pending. The company will issue a total of 560,000 common shares, about 16.0% of its outstanding shares after issuance, with no cash payment, which shareholders would bear as dilution. The filing states that BioNexus has not been awarded any government contract and that closing depends on technology acceptance, due diligence and approvals.
Share consideration: 410,000 shares for a stated US$3.5 million licence fee, plus 150,000 shares for 500,000 RYET ordinary shares, totaling 560,000 shares, or about 16.0% of outstanding common shares after issuance.
Royalty: RYET receives 10% of defined technology receipts actually collected, with no minimum royalty or annual platform fee.
Closing: either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
Government work: BioNexus has not been awarded any government contract, and any public-sector work would depend on government procurement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.